There are 412 resources available
47P - Digital spatial profiling reveals age-related disparities in immune microenvironment and aggressive phenotypes in triple-negative breast cancer
Presenter: Snijesh V P
Session: Lunch and Poster Display session
48P - Large-scale DNA organization of nuclei in DCIS ducts with adjacent invasive cancer
Presenter: Martial Guillaud
Session: Lunch and Poster Display session
49P - A ctDNA tool for identifying ESR1-mutated biology in ESR1-non-mutated hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Presenter: Isabel Garcia-Fructuoso
Session: Lunch and Poster Display session
50P - Circulating cytokines to predict pCR to neoadjuvant chemotherapy and nivolumab for ER+/HER2- BC: Analysis of the phase II GIADA trial
Presenter: Maria Vittoria Dieci
Session: Lunch and Poster Display session
51P - ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study
Presenter: Karthik Giridhar
Session: Lunch and Poster Display session
52P - Comparing the genomic landscape of de novo vs recurrent metastatic breast cancer by ctDNA and tissue profiling
Presenter: Federica Giugliano
Session: Lunch and Poster Display session
53P - Longitudinal ctDNA surveillance in older women with ER+ breast cancer who omit surgery and receive primary endocrine therapy
Presenter: Steffi Oesterreich
Session: Lunch and Poster Display session
54P - Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment
Presenter: Eva Valentina Klocker
Session: Lunch and Poster Display session
55P - Landscape of PIK3CA, PTEN, and AKT1 alterations in advanced breast cancer (ABC) using circulating tumor DNA (ctDNA): Next generation sequencing (NGS) in Asia and the Middle East (AME)
Presenter: Shaheenah Dawood
Session: Lunch and Poster Display session
56P - Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: A secondary analysis of the phase II PREDIX HER2 trial
Presenter: Ioannis Zerdes
Session: Lunch and Poster Display session